Description

• Description
• Certificate of Analysis
• HPLC
• Mass Spectrometry

N-Acetyl Selank Peptide – Research Grade

Product Code: NAS-5MG
Size: 5 mg
Form: Lyophilized Powder
Purity: ≥99% (HPLC)
Sequence: N-Acetyl–Thr–Lys–Pro–Arg–Pro–Gly–Pro–NH₂
Molecular Formula: C₃₃H₅₇N₁₁O₉
Molecular Weight: 751.9 g/mol
Storage: –20°C (Stable for 24 months unopened)
Solubility: Soluble in sterile water, PBS, or dilute acetic acid

---

Description

N-Acetyl Selank is a synthetic heptapeptide derivative of the endogenous immunomodulatory tetrapeptide Tuftsin, designed to enhance stability, bioavailability, and neurotropic activity. It is also known under the research title TP-7.

The addition of an acetyl group at the N-terminus and the Pro-Gly-Pro tripeptide at the C-terminus are believed to increase resistance to enzymatic degradation and facilitate blood-brain barrier permeability. This modification may improve tissue penetration and peptide half-life without significantly altering its mechanism of action.

Selank has been extensively studied for its potential anxiolytic, nootropic, and immunomodulatory properties in animal and preliminary clinical models. It is believed to influence neurochemical systems associated with stress, cognition, and immune regulation.

Potential Mechanisms of Action

1. GABAergic Modulation:
   Research indicates Selank may upregulate GABA receptor gene expression and modulate GABAergic neurotransmission, potentially producing anxiolytic and stabilizing effects in the central nervous system (Volkova et al., 2016).

2. Serotonergic System Interaction:
   Experimental studies suggest Selank can enhance serotonin metabolism in the brainstem, possibly through stimulating serotonin turnover or receptor sensitivity (Semenova et al., 2009).

3. Enkephalin System Regulation:
   Selank may inhibit enkephalin-degrading enzymes, leading to elevated levels of endogenous opioid peptides and enhanced mood regulation (Kost et al., 2001).

4. Neurotrophic Modulation (BDNF):
   Exposure to Selank has been reported to increase brain-derived neurotrophic factor (BDNF) expression in the hippocampus, which may promote neuroplasticity and resilience under stress.

5. Immunomodulatory Effects:
   Selank has been shown to normalize Th1/Th2 cytokine balance, potentially acting as an immunomodulator under stress-related and anxiety-asthenic conditions (Uchakina et al., 2008).

---

Chemical Information

---

Certificate of Analysis (COA)

---

HPLC Analysis (Representative Batch)

Instrumentation: Agilent 1260 Infinity
Column: C18 Reverse-Phase (4.6 × 250 mm, 5 µm)
Mobile Phase: A: 0.1% TFA in H₂O / B: 0.1% TFA in Acetonitrile
Gradient: 5–60% B over 30 min
Detection: 214 nm
Retention Time (Rt): 17.86 min
Purity: 99.38% (Area Normalization)

(Figure 1: Chromatogram showing a single dominant peak at 17.86 min corresponding to N-Acetyl Selank. No detectable secondary peaks >0.4%.)

---

Mass Spectrometry (ESI-MS)

(Figure 2: Mass spectrum showing the molecular ion peak at m/z 751.8, confirming synthesis accuracy and sequence integrity.)

---

Research Applications

N-Acetyl Selank is currently being studied in experimental models for its potential roles in:

• Anxiety and stress modulation

• Cognitive enhancement and neuroplasticity

• Serotonin and GABA regulation

• Enkephalin metabolism and mood stabilization

• Immunomodulation and cytokine balance

• Cholesterol and lipid metabolism regulation

---

Important Notice

This compound is intended for laboratory and research use only.
Not for human consumption, medical, therapeutic, or diagnostic purposes.
To be handled only by qualified professionals in a controlled laboratory setting.

---

References

1. Kozlovskaya M.M. et al. (2003). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol, 33(9): 853–860.

2. Volkova A. et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol., 7: 31.

3. Semenova T.P. et al. (2009). Eksperimental’naia i klinicheskaia farmakologiia, 72(4): 6–8.

4. Kost N.V. et al. (2001). Semax and Selank inhibit enkephalin-degrading enzymes from human serum. Bioorg Khimiya, 27(3): 180–183.

5. Zozulia A.A. et al. (2008). Clinical study of Selank in generalized anxiety and neurasthenia models. Zh Nevrol Psikhiatr Im S.S. Korsakova, 108(4): 38–48.